User login
As primary care doctors, we diagnosis and treat many patients with osteoarthritis. In fact, according to World Health Organization statistics, approximately 528 million people around the world suffer from some form of this type of arthritis. With the aging of the population and the obesity epidemic, the rate of osteoarthritis has increased 113% since 1990 and is predicted to continue to rise.
While the knee is the most commonly affected joint, osteoarthritis also frequently affects the hands and hips. The American Academy of Orthopaedic Surgeons issued guidelines concerning the management of osteoarthritis of the hip. The clinical guidelines are aimed at orthopedists, but it is important for primary care doctors be aware of them as well since we are the physicians who usually diagnose the disease, manage it in its early stages, and follow the patients with and after the orthopedist has undertaken any procedures.
While the complete set of guidelines is 80 pages long, strong recommendations have been made that everyone should be aware of. The role of non-steroidal anti-inflammatory drugs has been reconfirmed as a modality to improve pain and function. A recommendation against using intra-articular hyaluronic acid in the hip was made as the evidence shows it did not improve pain or function better than placebo. Conversely, intra-articular corticosteroids were shown to improve pain and function in the short-term and many primary care doctors provide this treatment in their practice.
These guidelines do a great job covering the totality of management of osteoarthritis of the hip, from conservation management to surgical and post-surgical treatments. Patients often come to us with their questions so not only is it important to know the evidence for what we do in our practices, we need to know what our orthopedic colleagues are doing. We will be the ones asked to do the pre-operative evaluations on these patients, so we need to understand the procedure and its risks. We will also manage these patients post-operatively and need to be aware of what the evidence shows.
Opioid use is also covered in the guidelines: they recommend against the use of opioids to control pain in these patients. In the age of the opioid epidemic, it is a good reminder to be cautious with these meds. It is also a good time to stress smoking cessation with patients.
The guidelines discuss adverse outcomes in patients with diabetes and/or obesity. As primary care physicians, we need to be aware of those risks and be sure our patients are medically optimized before signing that pre-operative form.
A new feature of these guidelines is a discussion on social detriments to health. This is important for many diseases that we treat and we often don’t realize the impact they can have on a patient’s health and recovery. Even if we know a patient would benefit from physical therapy, it doesn’t help them if the patient has no way to get to the appointment. Some patients have copays for every physical therapy session and just can’t afford it. Knowing what the patient needs medically is not enough. We need to understand how they can access that care. Some patients have no one to help them after hip surgery and may avoid doing it for that reason. As primary care doctors, we should be helping our patients access the care they need.
We need to be able to say that a procedure needs to be delayed in the face of poorly controlled disease, such as diabetes. As the rates of osteoarthritis continue to rise, we need to understand that it is not an inevitable age-based occurrence in a patient’s life but rather an inflammatory disease that causes great pain and dysfunction. Utilizing these guidelines and working with our orthopedic colleagues can help patients decrease pain, improve functioning, and enjoy life again.
Dr. Girgis practices family medicine in South River, New Jersey, and is a clinical assistant professor of family medicine at Robert Wood Johnson Medical School, New Brunswick, New Jersey. She was paid by Pfizer as a consultant on Paxlovid, paid by GlaxoSmithKline as a consultant for the Shingrix vaccine, and is the editor in chief of Physician’s Weekly.
As primary care doctors, we diagnosis and treat many patients with osteoarthritis. In fact, according to World Health Organization statistics, approximately 528 million people around the world suffer from some form of this type of arthritis. With the aging of the population and the obesity epidemic, the rate of osteoarthritis has increased 113% since 1990 and is predicted to continue to rise.
While the knee is the most commonly affected joint, osteoarthritis also frequently affects the hands and hips. The American Academy of Orthopaedic Surgeons issued guidelines concerning the management of osteoarthritis of the hip. The clinical guidelines are aimed at orthopedists, but it is important for primary care doctors be aware of them as well since we are the physicians who usually diagnose the disease, manage it in its early stages, and follow the patients with and after the orthopedist has undertaken any procedures.
While the complete set of guidelines is 80 pages long, strong recommendations have been made that everyone should be aware of. The role of non-steroidal anti-inflammatory drugs has been reconfirmed as a modality to improve pain and function. A recommendation against using intra-articular hyaluronic acid in the hip was made as the evidence shows it did not improve pain or function better than placebo. Conversely, intra-articular corticosteroids were shown to improve pain and function in the short-term and many primary care doctors provide this treatment in their practice.
These guidelines do a great job covering the totality of management of osteoarthritis of the hip, from conservation management to surgical and post-surgical treatments. Patients often come to us with their questions so not only is it important to know the evidence for what we do in our practices, we need to know what our orthopedic colleagues are doing. We will be the ones asked to do the pre-operative evaluations on these patients, so we need to understand the procedure and its risks. We will also manage these patients post-operatively and need to be aware of what the evidence shows.
Opioid use is also covered in the guidelines: they recommend against the use of opioids to control pain in these patients. In the age of the opioid epidemic, it is a good reminder to be cautious with these meds. It is also a good time to stress smoking cessation with patients.
The guidelines discuss adverse outcomes in patients with diabetes and/or obesity. As primary care physicians, we need to be aware of those risks and be sure our patients are medically optimized before signing that pre-operative form.
A new feature of these guidelines is a discussion on social detriments to health. This is important for many diseases that we treat and we often don’t realize the impact they can have on a patient’s health and recovery. Even if we know a patient would benefit from physical therapy, it doesn’t help them if the patient has no way to get to the appointment. Some patients have copays for every physical therapy session and just can’t afford it. Knowing what the patient needs medically is not enough. We need to understand how they can access that care. Some patients have no one to help them after hip surgery and may avoid doing it for that reason. As primary care doctors, we should be helping our patients access the care they need.
We need to be able to say that a procedure needs to be delayed in the face of poorly controlled disease, such as diabetes. As the rates of osteoarthritis continue to rise, we need to understand that it is not an inevitable age-based occurrence in a patient’s life but rather an inflammatory disease that causes great pain and dysfunction. Utilizing these guidelines and working with our orthopedic colleagues can help patients decrease pain, improve functioning, and enjoy life again.
Dr. Girgis practices family medicine in South River, New Jersey, and is a clinical assistant professor of family medicine at Robert Wood Johnson Medical School, New Brunswick, New Jersey. She was paid by Pfizer as a consultant on Paxlovid, paid by GlaxoSmithKline as a consultant for the Shingrix vaccine, and is the editor in chief of Physician’s Weekly.
As primary care doctors, we diagnosis and treat many patients with osteoarthritis. In fact, according to World Health Organization statistics, approximately 528 million people around the world suffer from some form of this type of arthritis. With the aging of the population and the obesity epidemic, the rate of osteoarthritis has increased 113% since 1990 and is predicted to continue to rise.
While the knee is the most commonly affected joint, osteoarthritis also frequently affects the hands and hips. The American Academy of Orthopaedic Surgeons issued guidelines concerning the management of osteoarthritis of the hip. The clinical guidelines are aimed at orthopedists, but it is important for primary care doctors be aware of them as well since we are the physicians who usually diagnose the disease, manage it in its early stages, and follow the patients with and after the orthopedist has undertaken any procedures.
While the complete set of guidelines is 80 pages long, strong recommendations have been made that everyone should be aware of. The role of non-steroidal anti-inflammatory drugs has been reconfirmed as a modality to improve pain and function. A recommendation against using intra-articular hyaluronic acid in the hip was made as the evidence shows it did not improve pain or function better than placebo. Conversely, intra-articular corticosteroids were shown to improve pain and function in the short-term and many primary care doctors provide this treatment in their practice.
These guidelines do a great job covering the totality of management of osteoarthritis of the hip, from conservation management to surgical and post-surgical treatments. Patients often come to us with their questions so not only is it important to know the evidence for what we do in our practices, we need to know what our orthopedic colleagues are doing. We will be the ones asked to do the pre-operative evaluations on these patients, so we need to understand the procedure and its risks. We will also manage these patients post-operatively and need to be aware of what the evidence shows.
Opioid use is also covered in the guidelines: they recommend against the use of opioids to control pain in these patients. In the age of the opioid epidemic, it is a good reminder to be cautious with these meds. It is also a good time to stress smoking cessation with patients.
The guidelines discuss adverse outcomes in patients with diabetes and/or obesity. As primary care physicians, we need to be aware of those risks and be sure our patients are medically optimized before signing that pre-operative form.
A new feature of these guidelines is a discussion on social detriments to health. This is important for many diseases that we treat and we often don’t realize the impact they can have on a patient’s health and recovery. Even if we know a patient would benefit from physical therapy, it doesn’t help them if the patient has no way to get to the appointment. Some patients have copays for every physical therapy session and just can’t afford it. Knowing what the patient needs medically is not enough. We need to understand how they can access that care. Some patients have no one to help them after hip surgery and may avoid doing it for that reason. As primary care doctors, we should be helping our patients access the care they need.
We need to be able to say that a procedure needs to be delayed in the face of poorly controlled disease, such as diabetes. As the rates of osteoarthritis continue to rise, we need to understand that it is not an inevitable age-based occurrence in a patient’s life but rather an inflammatory disease that causes great pain and dysfunction. Utilizing these guidelines and working with our orthopedic colleagues can help patients decrease pain, improve functioning, and enjoy life again.
Dr. Girgis practices family medicine in South River, New Jersey, and is a clinical assistant professor of family medicine at Robert Wood Johnson Medical School, New Brunswick, New Jersey. She was paid by Pfizer as a consultant on Paxlovid, paid by GlaxoSmithKline as a consultant for the Shingrix vaccine, and is the editor in chief of Physician’s Weekly.